Brasil Pack Trends 2020

BrasilPackTrends2020 31 packaging market: world and Brazi l Table 1.50 Historical trends and projections for beverage packaging consumption: Volume (tonnes) Material Thousand tonnes 2007 Thousand tonnes 2011 Average growth 2007-2011 Thousand tonnes 2015* Average growth 2011-2015* Glass 733.9 910.1 5.5% 1,035.5 3.3% Plastics 630.3 884.9 8.9% 1,102.9 5.7% Corrugated board 486.4 640.1 7.1% 779.5 5.0% Metals 319.1 428.9 7.7% 531.8 5.5% Paper 269.7 333.4 5.4% 414.1 5.6% Flexibles 62.2 73.3 4.2% 89.6 5.1% TOTAL 2,501.5 3,270.6 6.9% 3,953.4 4.9% *Estimate Source: DATAMARK In the last ten years, the pharmaceutical sales, including generics, OTC (over-the-counter) and other pharmaceuticals under medical prescription, have increased 43.5%, reaching 2.34 billion of unities at the end of 2011. The fast growth of basically all types of pharmaceuticals has stimulated the major pharmaceutical companies to invest in expanding of industrial facilities, clinical studies and acquisitions. About R$ 5 billion in investments, business and acquisitions shook the Brazilian pharmaceutical market in 2011. Major investments are also a way for the pharmaceutical companies to prepare to face a new era without the blockbuster patented products. The expiration of a patent generates, for the manufacturers and P&D holders, a loss of US$ 500 million in sales in Brazil, and in 2011, around 25 pharmaceuticals had their patents expire. In order to face this transformation, one of the main strategic initiatives by the sector giants is product innovation and investment in research to speed up the development of new therapeutic treatments. The considerable increase in the investments in research, caused by the patent expiration, compares with the growth of generic pharmaceuticals share in the Brazilian market, which closed 2011 with 20.5% of pharmaceutical sector sales. The packaging sector for pharmaceuticals, that ranges from laminated blisters and paperboard cartons to glass bottles, have gotten benefits from the soaring of the demand for generic pharmaceuticals, generating approximately R$ 606 million in 2011, an increase of 25% versus 2010, passing the 13% growth rate of the pharmaceutical sector. Table 1.5 shows the relationship of the ten largest companies of the sector in 2010 (by sales) (PORTAL FARMACÊUTICO, 2012; FÓRUM DE LÍDERES, s.d.). The OTC pharmaceuticals market is increasing, having been pushed mainly by the expansion of governmental healthcare programs, as well as the increase of the discretionary income of the Brazilian consumer. The growth of the C class’s purchasing power and the decrease in price of pharmaceuticals, thanks to the advent of the generics, has made pharmaceuticals more accessible to most of the Brazil’s population. The average spend per capita in 2012 was R$ 386.43, versus R$ 337 from 2011. Classes B and C will be mainly responsible for that consumption. Together, they correspond to 80% of the total, with spending of R$ 23 billion and R$ 27 billion, respectively. User industry: healthcare